Paul B. Manning, Director at Candel Therapeutics, Inc. (CADL), bought 1,250,000 shares at $6.00 ($7.5M) on 2024-12-16, disclosed to the SEC on 2024-12-18.
Open-market purchase of $7.5M CADL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.00 | 500,000 | $3.0M | 40.0% |
| 2 | $6.00 | 750,000 | $4.5M | 60.0% |
| Total | $6.00 avg | 1,250,000 | $7.5M | 100% |
| Filing → |
| VRCA | BUY | 2025-11-25 | $35.0M | — | Filing → |
| LQDA | SELL | 2025-09-02 | $37.9M | — | Filing → |
| TSHA | BUY | 2025-06-03 | $2.1M | — | Filing → |